Abstract:SummaryBackgroundHigh-dose dexamethasone is the standard initial treatment for patients with immune thrombocytopenia, but many patients still relapse and require further treatments. All-trans retinoic acid has been shown to exert immunomodulatory effects and promote thrombopoiesis, and so we aimed to assess the activity and safety of all-trans retinoic acid plus high-dose dexamethasone as a first-line treatment for newly diagnosed patients with immune thrombocytopenia.MethodsThis multicentre, open-label, randomised, controlled, phase 2 trial was done at six different tertiary medical centres in China. Eligible participants were adults (aged >18 years) with treatment-naive, newly diagnosed, primary immune thrombocytopenia who had either a platelet count of less than 30 × 109 platelets per L or a platelet count of less than 50 × 109 platelets per L and clinically significant bleeding. We randomly assigned (1:1) participants to receive either all-trans retinoic acid (10 mg orally twice daily for 12 weeks) plus high-dose dexamethasone (40 mg/day intravenously for 4 consecutive days) or high-dose dexamethasone alone using a central, web-based randomisation system. If patients did not respond by day 14, the 4-day course of dexamethasone was repeated. The primary endpoint was 6-month sustained response, defined as the maintenance of a platelet count of at least 30 × 109 platelets per L and at least 2-times higher than the baseline count and the absence of bleeding, with no need for rescue medication at this time. The primary endpoint was analysed by intention-to-treat and safety was assessed in all participants who received at least one dose of the study drug. This trial is registered with ClinicalTrials.gov, NCT04217148, and is now completed.FindingsBetween Jan 1, 2020, and June 30, 2020, 132 patients were randomly assigned to either all-trans retinoic acid plus high-dose dexamethasone (n=66) or high-dose dexamethasone alone (n=66). Three patients did not receive their allocated treatment, leaving 129 in the safety analysis set. At 6 months, a significantly higher proportion of participants in the all-trans retinoic acid plus high-dose dexamethasone group (45 [68%] of 66) than in the high-dose dexamethasone monotherapy group (27 [41%] of 66) had a sustained response (OR 3·095, 95% CI 1·516–6·318; p=0·0017). The most common adverse events were dry skin (31 [48%] of 64 patients), headaches (12 [19%]), and insomnia (12 [19%]) in the combination group, and insomnia (ten [15%] of 65 patients) and anxiety or mood disorders (eight [12%]) in the monotherapy group. Both treatments were well tolerated and no grade 4 or worse adverse events occurred. There were no treatment-related deaths.InterpretationThe combination of all-trans retinoic acid and high-dose dexamethasone was safe and active in newly diagnosed patients with primary immune thrombocytopenia, providing a sustained response. This regimen represents a potential first-line treatment in this setting, but further studies are needed to validate its efficacy and safety.FundingThe Beijing Municipal Science and Technology Commission, the National Natural Science Foundation of China, the Beijing Natural Science Foundation, the National Key Research and Development Program of China, and the Foundation for Innovative Research Groups of the National Natural Science Foundation of China.

High-dose dexamethasone or all-trans retinoic acid restores the balance of macrophage toward M 2 in Immune thrombocytopenia Running title : M 1 / M 2 polarization in immune thrombocytopenia

Distinct Alterations of CD68+CD163+ M2-like Macrophages and Myeloid-Derived Suppressor Cells in Newly Diagnosed Primary Immune Thrombocytopenia with or Without CR after High-Dose Dexamethasone Treatment.

Effects of High-Dose Dexamethasone on Regulating Interleukin-22 Production and Correcting Th1 and Th22 Polarization in Immune Thrombocytopenia

High-dose Dexamethasone Corrects Impaired Myeloid-Derived Suppressor Cell Function Via Ets1 in Immune Thrombocytopenia.

Low-Dose Decitabine Could Improve the Imbalance of M1/M2 Ratio in Immune Thrombocytopenia

Low-dose Decitabine Promotes M2 Macrophage Polarization in Patients with Primary Immune Thrombocytopenia Via Enhancing KLF4 Binding to PPAR Promoter

All-trans retinoic acid plus high-dose dexamethasone as first-line treatment for patients with newly diagnosed immune thrombocytopenia: a multicentre, open-label, randomised, controlled, phase 2 trial

The Role of M2 Macrophage in Primary Immune Thrombocytopenia

Low‐dose decitabine promotes M2 macrophage polarization in patients with primary immune thrombocytopenia via enhancing KLF4 binding to PPARγ promoter

High-dose Dexamethasone Shifts the Balance of Stimulatory and Inhibitory Fcγ Receptors on Monocytes in Patients with Primary Immune Thrombocytopenia

The Efficacy of High-Dose Dexamethasone vs. Other Treatments for Newly Diagnosed Immune Thrombocytopenia: A Meta-Analysis

Estrogen-sensitive activation of SGK1 induces M2 macrophages with anti-inflammatory properties and a Th2 response at the maternal–fetal interface

High-dose Dexamethasone Modulates Serum Cytokine Profile in Patients with Primary Immune Thrombocytopenia.

Cd68(+) Cd163(+) M2-Like Macrophages And Myeloid-Derived Suppressor Cells In Primary Immune Thrombocytopenia

The Abnormal Function of CD39+ Regulatory T Cells Could Be Corrected by High-Dose Dexamethasone in Patients with Primary Immune Thrombocytopenia

M2 macrophages, but not M1 macrophages, support megakaryopoiesis by upregulating PI3K-AKT pathway activity

High‐dose dexamethasone plus recombinant human thrombopoietin vs high‐dose dexamethasone alone as frontline treatment for newly diagnosed adult primary immune thrombocytopenia: A prospective, multicenter, randomized trial

Efficacy and safety of treatments in newly diagnosed adult primary immune thrombocytopenia: A systematic review and network meta-analysis

[Experimental Study for Thrombocytopenic Purpura Therapy by Targeting Macrophages in Liver and Spleen].

Downregulation of Microrna-155-5p Prevents Immune Thrombocytopenia by Promoting Macrophage M2 Polarization Via the SOCS1-dependent PD1/PDL1 Pathway.

Glucocorticoid receptor modulates myeloid-derived suppressor cell function via mitochondria respiration and metabolism in immune thrombocytopenia